New Weight-loss Drug Halves Knee Arthritis Pain for Many Patients

WHO:

The Washington Post - The article concerns retatrutide, a weight-loss drug that had not yet been approved by the FDA.

[UNKNOWN] - Inc - Researchers at Northwestern University conducted two phase 3 trials of an experimental weight-loss drug.

[UNKNOWN] - Inc - The trials involved patients with osteoarthritis; the article reports that nearly 7 in 10 patients experienced reduced pain.

WHAT:

The Washington Post - A major study found that retatrutide may also ease knee pain.

The Washington Post - Retatrutide led to some of the greatest declines in body weight seen with any GLP-1-related drug in several large trials.

[UNKNOWN] - Inc - High doses of an experimental weight-loss drug cut osteoarthritis pain in half for nearly 7 in 10 patients.

[UNKNOWN] - Inc - The reported pain benefit was described as unexpected.

HOW:

[UNKNOWN] - Inc - The findings came from two phase 3 trials conducted by researchers at Northwestern University.

The Washington Post - The article describes retatrutide as a GLP-1-related drug.

(UPDATED November 11, 2026 13:06 UTC)

Experimental weight-loss drug retatrutide sharply reduced knee pain in major trials, while also producing substantial weight loss. Nearly seven in ten patients with osteoarthritis saw their pain cut in half at high doses. Northwestern researchers reported the unexpected findings from two phase three trials.